Drug resistance in colorectal cancer: An epigenetic overview.

[1]  Shanshan Wang,et al.  Inactivation of the tumor suppressor p53 by long noncoding RNA RMRP , 2021, Proceedings of the National Academy of Sciences.

[2]  Y. Zuo,et al.  MiR-454-3p Promotes Oxaliplatin Resistance by Targeting PTEN in Colorectal Cancer , 2021, Frontiers in Oncology.

[3]  P. Spellman,et al.  The impact of tumor epithelial and microenvironmental heterogeneity on treatment responses in HER2+ breast cancer , 2021, JCI insight.

[4]  Yuquan Wei,et al.  Genomic evolution and diverse models of systemic metastases in colorectal cancer , 2021, Gut.

[5]  A. Jemal,et al.  Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries , 2021, CA: a cancer journal for clinicians.

[6]  R. Kolhe,et al.  The clinical relevance of gene expression based prognostic signatures in colorectal cancer. , 2021, Biochimica et biophysica acta. Reviews on cancer.

[7]  G. Kroemer,et al.  Ferroptosis: molecular mechanisms and health implications , 2020, Cell Research.

[8]  Xinxiang Li,et al.  Tumor-derived exosomal miR-934 induces macrophage M2 polarization to promote liver metastasis of colorectal cancer , 2020, Journal of Hematology & Oncology.

[9]  Y. Assaraf,et al.  Surmounting cancer drug resistance: New insights from the perspective of N6-methyladenosine RNA modification. , 2020, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[10]  D. Klionsky,et al.  Ferroptosis: machinery and regulation , 2020, Autophagy.

[11]  Bang Hu,et al.  lncRNA UCA1 Contributes to 5-Fluorouracil Resistance of Colorectal Cancer Cells Through miR-23b-3p/ZNF281 Axis , 2020, OncoTargets and therapy.

[12]  Huidong Shi,et al.  Autocrine IL6-Mediated Activation of the STAT3–DNMT Axis Silences the TNFα–RIP1 Necroptosis Pathway to Sustain Survival and Accumulation of Myeloid-Derived Suppressor Cells , 2020, Cancer Research.

[13]  Lili Yan,et al.  Combinative treatment of β-elemene and cetuximab is sensitive to KRAS mutant colorectal cancer cells by inducing ferroptosis and inhibiting epithelial-mesenchymal transformation , 2020, Theranostics.

[14]  K. Polyak,et al.  Intratumor Heterogeneity: The Rosetta Stone of Therapy Resistance. , 2020, Cancer cell.

[15]  Yue Hu,et al.  Inhibition of miR-19a partially reversed the resistance of colorectal cancer to oxaliplatin via PTEN/PI3K/AKT pathway , 2020, Aging.

[16]  W. El-Deiry,et al.  Targeting apoptosis in cancer therapy , 2020, Nature Reviews Clinical Oncology.

[17]  Jianwen Hu,et al.  The novel long noncoding RNA CRART16 confers cetuximab resistance in colorectal cancer cells by enhancing ERBB3 expression via miR-371a-5p , 2020, Cancer Cell International.

[18]  Qi Zhang,et al.  Hsa_circ_001680 affects the proliferation and migration of CRC and mediates its chemoresistance by regulating BMI1 through miR-340 , 2020, Molecular Cancer.

[19]  Xianghuo He,et al.  Hypoxia induced LUCAT1/PTBP1 axis modulates cancer cell viability and chemotherapy response , 2020, Molecular Cancer.

[20]  S. M. Toor,et al.  Transcriptomic profiling disclosed the role of DNA methylation and histone modifications in tumor-infiltrating myeloid-derived suppressor cell subsets in colorectal cancer , 2020, Clinical Epigenetics.

[21]  Ye Zhang,et al.  Ferritin Light Chain (FTL) competes with long noncoding RNA Linc00467 for miR-133b binding site to regulate chemoresistance and metastasis of colorectal cancer. , 2020, Carcinogenesis.

[22]  Shouping Xu,et al.  Inhibition of tumor propellant glutathione peroxidase 4 induces ferroptosis in cancer cells and enhances anticancer effect of cisplatin , 2020, Journal of cellular physiology.

[23]  M. Guan,et al.  Long noncoding RNA CCAL transferred from fibroblasts by exosomes promotes chemoresistance of colorectal cancer cells , 2020, International journal of cancer.

[24]  He Zhou,et al.  LncRNA‐cCSC1 modulates cancer stem cell properties in colorectal cancer via activation of the Hedgehog signaling pathway , 2020, Journal of cellular biochemistry.

[25]  H. Deng,et al.  Temporal DNA methylation pattern and targeted therapy in colitis-associated cancer. , 2019, Carcinogenesis.

[26]  Jie Yang,et al.  Silencing or inhibition of H3K79 methyltransferase DOT1L induces cell cycle arrest by epigenetically modulating c-Myc expression in colorectal cancer , 2019, Clinical Epigenetics.

[27]  Hong-Sheng Zhang,et al.  TSPAN8 promotes colorectal cancer cell growth and migration in LSD1-dependent manner. , 2019, Life sciences.

[28]  Capucine Van Rechem,et al.  Histone Lysine Methylation Dynamics Control EGFR DNA Copy Number Amplification. , 2019, Cancer discovery.

[29]  Liang Huang,et al.  SNHG14 stimulates cell autophagy to facilitate cisplatin resistance of colorectal cancer by regulating miR-186/ATG14 axis. , 2019, Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie.

[30]  D. Xie,et al.  LncRNA RPPH1 promotes colorectal cancer metastasis by interacting with TUBB3 and by promoting exosomes-mediated macrophage M2 polarization , 2019, Cell Death & Disease.

[31]  M. Esteller,et al.  Epigenetic EGFR Gene Repression Confers Sensitivity to Therapeutic BRAFV600E Blockade in Colon Neuroendocrine Carcinomas , 2019, Clinical Cancer Research.

[32]  Y. Liang,et al.  Dichloroacetate Overcomes Oxaliplatin Chemoresistance in Colorectal Cancer through the miR-543/PTEN/Akt/mTOR Pathway , 2019, Journal of Cancer.

[33]  L. Harris,et al.  Reduction of Global H3K27me3 Enhances HER2/ErbB2 Targeted Therapy. , 2019, Cell reports.

[34]  Y. Zhang,et al.  circHIPK3 promotes oxaliplatin-resistance in colorectal cancer through autophagy by sponging miR-637 , 2019, EBioMedicine.

[35]  C. Shun,et al.  Metabolic targeting of HIF-1α potentiates the therapeutic efficacy of oxaliplatin in colorectal cancer , 2019, Oncogene.

[36]  C. Simpson,et al.  LSD1 Inhibition Promotes Epithelial Differentiation through Derepression of Fate-Determining Transcription Factors , 2019, Cell reports.

[37]  G. Lippi,et al.  Concise update on colorectal cancer epidemiology. , 2019, Annals of translational medicine.

[38]  B. Shi,et al.  Effects of histone deacetylase inhibitors on ATP-binding cassette transporters in lung cancer A549 and colorectal cancer HCT116 cells. , 2019, Oncology letters.

[39]  Anupriya,et al.  Drugs Targeting Epigenetic Modifications and Plausible Therapeutic Strategies Against Colorectal Cancer , 2019, Front. Pharmacol..

[40]  Hanshao Liu,et al.  Elevating H3K27me3 level sensitizes colorectal cancer to oxaliplatin , 2019, Journal of molecular cell biology.

[41]  Yan Ding,et al.  CAFs secreted exosomes promote metastasis and chemotherapy resistance by enhancing cell stemness and epithelial-mesenchymal transition in colorectal cancer , 2019, Molecular Cancer.

[42]  L. Altucci,et al.  Identification of a novel quinoline-based DNA demethylating compound highly potent in cancer cells , 2019, Clinical Epigenetics.

[43]  E. Richtig,et al.  Commonly integrated epigenetic modifications of differentially expressed genes lead to adaptive resistance in cancer , 2019, Epigenomics.

[44]  X. Fang,et al.  Epigenetically Down-Regulated Acetyltransferase PCAF Increases the Resistance of Colorectal Cancer to 5-Fluorouracil1 , 2019, Neoplasia.

[45]  D. Traver,et al.  EGFR is required for Wnt9a/Fzd9b signalling specificity in haematopoietic stem cells , 2019, Nature Cell Biology.

[46]  M. Bulyk,et al.  The multiple mechanisms that regulate p53 activity and cell fate , 2019, Nature Reviews Molecular Cell Biology.

[47]  B. Li,et al.  Ferroptosis, a new form of cell death: opportunities and challenges in cancer , 2019, Journal of Hematology & Oncology.

[48]  L. Du,et al.  Exosome-transmitted miR-128-3p increase chemosensitivity of oxaliplatin-resistant colorectal cancer , 2019, Molecular Cancer.

[49]  Peng Li,et al.  LncRNA CACS15 contributes to oxaliplatin resistance in colorectal cancer by positively regulating ABCC1 through sponging miR-145. , 2019, Archives of biochemistry and biophysics.

[50]  R. Chen,et al.  MiR-483-3p regulates oxaliplatin resistance by targeting FAM171B in human colorectal cancer cells , 2019, Artificial cells, nanomedicine, and biotechnology.

[51]  Yang Wu,et al.  Long noncoding RNA and mRNA profiling in cetuximab‐resistant colorectal cancer cells by RNA sequencing analysis , 2019, Cancer medicine.

[52]  B. Neyns,et al.  Phase I clinical trial of decitabine (5-aza-2'-deoxycytidine) administered by hepatic arterial infusion in patients with unresectable liver-predominant metastases , 2019, ESMO Open.

[53]  O. Barbash,et al.  Targeting epigenetic modifications in cancer therapy: erasing the roadmap to cancer , 2019, Nature Medicine.

[54]  Shuyi Wang,et al.  miR-195-5p/NOTCH2-mediated EMT modulates IL-4 secretion in colorectal cancer to affect M2-like TAM polarization , 2019, Journal of Hematology & Oncology.

[55]  Y. Wan,et al.  EZH2 Inhibitor GSK126 Suppresses Antitumor Immunity by Driving Production of Myeloid-Derived Suppressor Cells. , 2019, Cancer research.

[56]  J. Gaedcke,et al.  The histone methyltransferase DOT1L is required for proper DNA damage response, DNA repair, and modulates chemotherapy responsiveness , 2019, Clinical Epigenetics.

[57]  P. Pauwels,et al.  Overcoming Intrinsic and Acquired Cetuximab Resistance in RAS Wild-Type Colorectal Cancer: An In Vitro Study on the Expression of HER Receptors and the Potential of Afatinib , 2019, Cancers.

[58]  Ji-Young Kim,et al.  FOXO1 degradation via G9a-mediated methylation promotes cell proliferation in colon cancer , 2018, Nucleic acids research.

[59]  J. Huo,et al.  Histone deacetylase 6 selective inhibitor ACY1215 inhibits cell proliferation and enhances the chemotherapeutic effect of 5-fluorouracil in HCT116 cells. , 2019, Annals of translational medicine.

[60]  P. Buckhaults,et al.  Myeloid-Derived Suppressor Cells Produce IL-10 to Elicit DNMT3b-Dependent IRF8 Silencing to Promote Colitis-Associated Colon Tumorigenesis , 2018, Cell reports.

[61]  Anton Simeonov,et al.  KDM5 Histone Demethylase Activity Links Cellular Transcriptomic Heterogeneity to Therapeutic Resistance. , 2018, Cancer cell.

[62]  S. Skvortsov,et al.  Therapy resistance mediated by cancer stem cells. , 2018, Seminars in cancer biology.

[63]  Guiyu Wang,et al.  Long non-coding RNA H19 confers 5-Fu resistance in colorectal cancer by promoting SIRT1-mediated autophagy , 2018, Cell Death & Disease.

[64]  P. Liu,et al.  ANRIL promotes chemoresistance via disturbing expression of ABCC1 by regulating the expression of Let-7a in colorectal cancer , 2018, Bioscience reports.

[65]  Weiqun Peng,et al.  miR-137 mediates the functional link between c-Myc and EZH2 that regulates cisplatin resistance in ovarian cancer , 2018, Oncogene.

[66]  G. Rosner,et al.  A Phase I Trial of a Guadecitabine (SGI-110) and Irinotecan in Metastatic Colorectal Cancer Patients Previously Exposed to Irinotecan , 2018, Clinical Cancer Research.

[67]  G. Freeman,et al.  LSD1 Ablation Stimulates Anti-tumor Immunity and Enables Checkpoint Blockade , 2018, Cell.

[68]  Herbert Yu,et al.  A G3BP1-Interacting lncRNA Promotes Ferroptosis and Apoptosis in Cancer via Nuclear Sequestration of p53. , 2018, Cancer research.

[69]  L. Ding,et al.  Carcinoma-associated fibroblasts promote the stemness and chemoresistance of colorectal cancer by transferring exosomal lncRNA H19 , 2018, Theranostics.

[70]  Qiang Yu,et al.  KDM6B Counteracts EZH2-Mediated Suppression of IGFBP5 to Confer Resistance to PI3K/AKT Inhibitor Treatment in Breast Cancer , 2018, Molecular Cancer Therapeutics.

[71]  A. Hauschild,et al.  PD‐1 Blockade with Cemiplimab in Advanced Cutaneous Squamous‐Cell Carcinoma , 2018, The New England journal of medicine.

[72]  J. Králová,et al.  Epigenetic agents in combined anticancer therapy. , 2018, Future medicinal chemistry.

[73]  W. Deng,et al.  KDM4B promotes DNA damage response via STAT3 signaling and is a target of CREB in colorectal cancer cells , 2018, Molecular and Cellular Biochemistry.

[74]  N. Bercovici,et al.  Macrophages impede CD8 T cells from reaching tumor cells and limit the efficacy of anti–PD-1 treatment , 2018, Proceedings of the National Academy of Sciences.

[75]  R. Fu,et al.  miR-206 regulates 5-FU resistance by targeting Bcl-2 in colon cancer cells , 2018, OncoTargets and therapy.

[76]  M. Redrado,et al.  miR-146a targets c-met and abolishes colorectal cancer liver metastasis. , 2018, Cancer letters.

[77]  A. Shaw,et al.  Tumour heterogeneity and resistance to cancer therapies , 2018, Nature Reviews Clinical Oncology.

[78]  B. Williams,et al.  (−)‐Epigallocatechin‐3‐gallate and EZH2 inhibitor GSK343 have similar inhibitory effects and mechanisms of action on colorectal cancer cells , 2018, Clinical and experimental pharmacology & physiology.

[79]  G. Garcia-Manero,et al.  Therapeutic choices after hypomethylating agent resistance for myelodysplastic syndromes , 2017, Current opinion in hematology.

[80]  P. Datta,et al.  STRAP Promotes Stemness of Human Colorectal Cancer via Epigenetic Regulation of the NOTCH Pathway. , 2017, Cancer research.

[81]  T. Yeatman,et al.  lncRNA MIR100HG-derived miR-100 and miR-125b mediate cetuximab resistance via Wnt/β-catenin signaling , 2017, Nature Medicine.

[82]  P. Giresi,et al.  Repression of Stress-Induced LINE-1 Expression Protects Cancer Cell Subpopulations from Lethal Drug Exposure. , 2017, Cancer cell.

[83]  A. Zaniboni,et al.  The role of primary tumour sidedness, EGFR gene copy number and EGFR promoter methylation in RAS/BRAF wild-type colorectal cancer patients receiving irinotecan/cetuximab , 2017, British Journal of Cancer.

[84]  Jinhua Wu,et al.  Maintenance of cancer stemness by miR-196b-5p contributes to chemoresistance of colorectal cancer cells via activating STAT3 signaling pathway , 2017, Oncotarget.

[85]  Cun-Yu Wang,et al.  KDM3 epigenetically controls tumorigenic potentials of human colorectal cancer stem cells through Wnt/β-catenin signalling , 2017, Nature Communications.

[86]  R. Weinberg,et al.  EMT, CSCs, and drug resistance: the mechanistic link and clinical implications , 2017, Nature Reviews Clinical Oncology.

[87]  Wei Wang,et al.  Critical threshold levels of DNA methyltransferase 1 are required to maintain DNA methylation across the genome in human cancer cells. , 2017, Genome research.

[88]  Peter A. Jones,et al.  Combination epigenetic therapy in metastatic colorectal cancer (mCRC) with subcutaneous 5-azacitidine and entinostat: a phase 2 consortium/stand Up 2 cancer study , 2017, Oncotarget.

[89]  Shawn M. Gillespie,et al.  Adaptive Chromatin Remodeling Drives Glioblastoma Stem Cell Plasticity and Drug Tolerance. , 2017, Cell stem cell.

[90]  Zhi-wei Yu,et al.  The lncRNA CRNDE promotes colorectal cancer cell proliferation and chemoresistance via miR-181a-5p-mediated regulation of Wnt/β-catenin signaling , 2017, Molecular Cancer.

[91]  C. Liao,et al.  Epigenetic changes in histone acetylation underpin resistance to the topoisomerase I inhibitor irinotecan , 2016, Nucleic acids research.

[92]  Ge Zhang,et al.  Therapeutic Advances in Gastroenterology Targeting Histone Methylation for Colorectal Cancer , 2022 .

[93]  S. M. Toor,et al.  Increased Levels of Circulating and Tumor-Infiltrating Granulocytic Myeloid Cells in Colorectal Cancer Patients , 2016, Front. Immunol..

[94]  H. Sabit,et al.  Procaine Induces Epigenetic Changes in HCT116 Colon Cancer Cells , 2016, Genetics research international.

[95]  S. Jackson,et al.  G9a inhibition potentiates the anti-tumour activity of DNA double-strand break inducing agents by impairing DNA repair independent of p53 status , 2016, Cancer letters.

[96]  B. Broom,et al.  Phase I/II study of azacitidine and capecitabine/oxaliplatin (CAPOX) in refractory CIMP-high metastatic colorectal cancer: evaluation of circulating methylated vimentin , 2016, Oncotarget.

[97]  S. Ozawa,et al.  Combination of the histone deacetylase inhibitor depsipeptide and 5-fluorouracil upregulates major histocompatibility complex class II and p21 genes and activates caspase-3/7 in human colon cancer HCT-116 cells , 2016, Oncology reports.

[98]  Pei-Ming Yang,et al.  EZH2 inhibitors transcriptionally upregulate cytotoxic autophagy and cytoprotective unfolded protein response in human colorectal cancer cells. , 2016, American journal of cancer research.

[99]  P. Trojer,et al.  An inhibitor of KDM5 demethylases reduces survival of drug-tolerant cancer cells. , 2016, Nature chemical biology.

[100]  Jimmy D Bell,et al.  Synergy between histone deacetylase inhibitors and DNA-damaging agents is mediated by histone deacetylase 2 in colorectal cancer , 2016, Oncotarget.

[101]  Xi Luo,et al.  EZH2 promotes colorectal cancer stem-like cell expansion by activating p21cip1-Wnt/β-catenin signaling , 2016, Oncotarget.

[102]  P. Munster,et al.  A phase I trial of panobinostat and epirubicin in solid tumors with a dose expansion in patients with sarcoma. , 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

[103]  S. Alahari,et al.  Regulation of epithelial-mesenchymal transition through epigenetic and post-translational modifications , 2016, Molecular Cancer.

[104]  S. Minucci,et al.  Inhibition of histone deacetylases in cancer therapy: lessons from leukaemia , 2016, British Journal of Cancer.

[105]  H. Xing,et al.  Histone deacetylase 2 regulates doxorubicin (Dox) sensitivity of colorectal cancer cells by targeting ABCB1 transcription , 2016, Cancer Chemotherapy and Pharmacology.

[106]  C. Hsieh,et al.  Human ATP-Binding Cassette Transporter ABCG2 Confers Resistance to CUDC-907, a Dual Inhibitor of Histone Deacetylase and Phosphatidylinositol 3-Kinase. , 2016, Molecular pharmaceutics.

[107]  Liao Jianping,et al.  Pre-clinical characterization of 4SC-202, a novel class I HDAC inhibitor, against colorectal cancer cells , 2016, Tumor Biology.

[108]  V. Sanz-Moreno,et al.  Epigenetic switch drives the conversion of fibroblasts into proinvasive cancer-associated fibroblasts , 2015, Nature Communications.

[109]  Y. Li,et al.  Interindividual epigenetic variation in ABCB1 promoter and its relationship with ABCB1 expression and function in healthy Chinese subjects. , 2015, British journal of clinical pharmacology.

[110]  Greta Varchi,et al.  A SMYD3 Small‐Molecule Inhibitor Impairing Cancer Cell Growth , 2015, Journal of cellular physiology.

[111]  William M. Grady,et al.  Epigenetic Alterations in Colorectal Cancer: Emerging Biomarkers. , 2015, Gastroenterology.

[112]  S. Iwakawa,et al.  Effects of Decitabine on Invasion and Exosomal Expression of miR-200c and miR-141 in Oxaliplatin-Resistant Colorectal Cancer Cells. , 2015, Biological & pharmaceutical bulletin.

[113]  Trevor J Pugh,et al.  DNA-Demethylating Agents Target Colorectal Cancer Cells by Inducing Viral Mimicry by Endogenous Transcripts , 2015, Cell.

[114]  X. Cen,et al.  Targeting protein arginine methyltransferase 5 inhibits colorectal cancer growth by decreasing arginine methylation of eIF4E and FGFR3 , 2015, Oncotarget.

[115]  Huamin Wang,et al.  Long non-coding RNA CCAL regulates colorectal cancer progression by activating Wnt/β-catenin signalling pathway via suppression of activator protein 2α , 2015, Gut.

[116]  Xinbing Sui,et al.  The role of STAT3 in autophagy , 2015, Autophagy.

[117]  Xiaojian Wu,et al.  DZNep inhibits the proliferation of colon cancer HCT116 cells by inducing senescence and apoptosis , 2015, Acta pharmaceutica Sinica. B.

[118]  P. Johnston,et al.  HDAC Inhibition Overcomes Acute Resistance to MEK Inhibition in BRAF-Mutant Colorectal Cancer by Downregulation of c-FLIPL , 2015, Clinical Cancer Research.

[119]  Jing Wang,et al.  MicroRNA-520g Confers Drug Resistance by Regulating p21 Expression in Colorectal Cancer* , 2015, The Journal of Biological Chemistry.

[120]  M. Tschan,et al.  TWIST1 and TWIST2 promoter methylation and protein expression in tumor stroma influence the epithelial-mesenchymal transition-like tumor budding phenotype in colorectal cancer , 2014, Oncotarget.

[121]  J. Doroshow,et al.  A phase I, pharmacokinetic, and pharmacodynamic evaluation of the DNA methyltransferase inhibitor 5-fluoro-2′-deoxycytidine, administered with tetrahydrouridine , 2015, Cancer Chemotherapy and Pharmacology.

[122]  A. Mai,et al.  New Insights on the Mechanism of Quinoline-based DNA Methyltransferase Inhibitors* , 2014, The Journal of Biological Chemistry.

[123]  X. Hua,et al.  EZH2 inhibition enhances the efficacy of an EGFR inhibitor in suppressing colon cancer cells , 2014, Cancer biology & therapy.

[124]  K. Young,et al.  LIF negatively regulates tumor suppressor p53 through Stat3/ID1/MDM2 in colorectal cancers , 2014, Nature Communications.

[125]  Sarah A Heerboth,et al.  Drug Resistance in Cancer: An Overview , 2014, Cancers.

[126]  M. Abaza,et al.  Valproic acid, an anti-epileptic drug and a histone deacetylase inhibitor, in combination with proteasome inhibitors exerts antiproliferative, pro-apoptotic and chemosensitizing effects in human colorectal cancer cells: underlying molecular mechanisms. , 2014, International journal of molecular medicine.

[127]  S. Emmrich,et al.  LincRNAs MONC and MIR100HG act as oncogenes in acute megakaryoblastic leukemia , 2014, Molecular Cancer.

[128]  Z. Zou,et al.  Combination of Gefitinib and DNA Methylation Inhibitor Decitabine Exerts Synergistic Anti-Cancer Activity in Colon Cancer Cells , 2014, PloS one.

[129]  K. Hirata,et al.  Combination Chemotherapy of Azacitidine and Cetuximab for Therapy-Related Acute Myeloid Leukemia following Oxaliplatin for Metastatic Colorectal Cancer , 2014, Case Reports in Oncology.

[130]  Y. Surh,et al.  Epigenetic modification of Nrf2 in 5-fluorouracil-resistant colon cancer cells: involvement of TET-dependent DNA demethylation , 2014, Cell Death and Disease.

[131]  S. Flis,et al.  DNA Methyltransferase Inhibitors Improve the Effect of Chemotherapeutic Agents in SW48 and HT-29 Colorectal Cancer Cells , 2014, PloS one.

[132]  M. Esteller,et al.  Epigenetic Inactivation of the BRCA1 Interactor SRBC and Resistance to Oxaliplatin in Colorectal Cancer , 2013, Journal of the National Cancer Institute.

[133]  G. Schett,et al.  The Wnt antagonists DKK1 and SFRP1 are downregulated by promoter hypermethylation in systemic sclerosis , 2013, Annals of the rheumatic diseases.

[134]  Dong Eun Kim,et al.  BIX-01294 induces autophagy-associated cell death via EHMT2/G9a dysfunction and intracellular reactive oxygen species production , 2013, Autophagy.

[135]  Andrea Bertotti,et al.  Amplification of the MET receptor drives resistance to anti-EGFR therapies in colorectal cancer. , 2013, Cancer discovery.

[136]  José L. Medina-Franco,et al.  Molecular Modeling Studies of the Novel Inhibitors of DNA Methyltransferases SGI-1027 and CBC12: Implications for the Mechanism of Inhibition of DNMTs , 2013, PloS one.

[137]  R. Soldi,et al.  A phase I/II study of decitabine in combination with panitumumab in patients with wild-type (wt) KRAS metastatic colorectal cancer , 2013, Investigational New Drugs.

[138]  A. Jankowska,et al.  Increased CDA Expression/Activity in Males Contributes to Decreased Cytidine Analog Half-Life and Likely Contributes to Worse Outcomes with 5-Azacytidine or Decitabine Therapy , 2013, Clinical Cancer Research.

[139]  M. Dawson,et al.  Cancer Epigenetics: From Mechanism to Therapy , 2012, Cell.

[140]  T. Golub,et al.  Tumour micro-environment elicits innate resistance to RAF inhibitors through HGF secretion , 2012, Nature.

[141]  K. Mimori,et al.  MicroRNA-10b is a Prognostic Indicator in Colorectal Cancer and Confers Resistance to the Chemotherapeutic Agent 5-Fluorouracil in Colorectal Cancer Cells , 2012, Annals of Surgical Oncology.

[142]  E. Bandrés,et al.  MicroRNA‐451 Is Involved in the Self‐renewal, Tumorigenicity, and Chemoresistance of Colorectal Cancer Stem Cells , 2011, Stem cells.

[143]  Xi Chen,et al.  BVES regulates EMT in human corneal and colon cancer cells and is silenced via promoter methylation in human colorectal carcinoma. , 2011, The Journal of clinical investigation.

[144]  P. Jänne,et al.  Activation of ERBB2 Signaling Causes Resistance to the EGFR-Directed Therapeutic Antibody Cetuximab , 2011, Science Translational Medicine.

[145]  R. Kurzrock,et al.  Autophagy as a target for anticancer therapy , 2011, Nature Reviews Clinical Oncology.

[146]  M. Lai,et al.  MiR-148a promotes apoptosis by targeting Bcl-2 in colorectal cancer , 2011, Cell Death and Differentiation.

[147]  Tae Won Kim,et al.  The histone deacetylase inhibitor PXD101 increases the efficacy of irinotecan in in vitro and in vivo colon cancer models , 2011, Cancer Chemotherapy and Pharmacology.

[148]  Tianhui Hu,et al.  Convergence between Wnt-β-catenin and EGFR signaling in cancer , 2010, Molecular Cancer.

[149]  Ben S. Wittner,et al.  A Chromatin-Mediated Reversible Drug-Tolerant State in Cancer Cell Subpopulations , 2010, Cell.

[150]  Tetsuo Yoshida,et al.  Functional screening identifies a microRNA, miR‐491 that induces apoptosis by targeting Bcl‐XL in colorectal cancer cells , 2009, International journal of cancer.

[151]  Li Lin,et al.  A novel small molecule inhibits STAT3 phosphorylation and DNA binding activity and exhibits potent growth suppressive activity in human cancer cells , 2010, Molecular Cancer.

[152]  Laura Vidal,et al.  Phase I Study of MG98, an Oligonucleotide Antisense Inhibitor of Human DNA Methyltransferase 1, Given as a 7-Day Infusion in Patients with Advanced Solid Tumors , 2009, Clinical Cancer Research.

[153]  F. Formelli,et al.  Valproic acid enhances bosutinib cytotoxicity in colon cancer cells , 2009, International journal of cancer.

[154]  C. Blanke,et al.  Phase II trial of romidepsin (NSC-630176) in previously treated colorectal cancer patients with advanced disease: a Southwest Oncology Group study (S0336) , 2009, Investigational New Drugs.

[155]  S. Bates,et al.  Histone Modifications at the ABCG2 Promoter following Treatment with Histone Deacetylase Inhibitor Mirror Those in Multidrug-Resistant Cells , 2008, Molecular Cancer Research.

[156]  Andreas Schätzlein,et al.  Phase I and pharmacodynamic trial of the DNA methyltransferase inhibitor decitabine and carboplatin in solid tumors. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[157]  M. Fishman,et al.  Phase I trial of histone deacetylase inhibition by valproic acid followed by the topoisomerase II inhibitor epirubicin in advanced solid tumors: a clinical and translational study. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[158]  M. Sehested,et al.  The histone deacetylase inhibitor PXD101 synergises with 5-fluorouracil to inhibit colon cancer cell growth in vitro and in vivo , 2007, Cancer Chemotherapy and Pharmacology.

[159]  Kenichi Sugihara,et al.  Effect of Combined Therapy With Low-Dose 5-Aza-2′-Deoxycytidine and Irinotecan on Colon Cancer Cell Line HCT-15 , 2007, Annals of Surgical Oncology.

[160]  E. Pérez-Cárdenas,et al.  Hydralazine target: From blood vessels to the epigenome , 2006, Journal of Translational Medicine.

[161]  C. Pérez-Plasencia,et al.  Antineoplastic effects of the DNA methylation inhibitor hydralazine and the histone deacetylase inhibitor valproic acid in cancer cell lines , 2006, Cancer Cell International.

[162]  Frank Lyko,et al.  Epigenetic reactivation of tumor suppressor genes by a novel small-molecule inhibitor of human DNA methyltransferases. , 2005, Cancer research.

[163]  H. Lührs,et al.  Histone-deacetylase inhibitors induce the cathelicidin LL-37 in gastrointestinal cells. , 2004, Molecular immunology.

[164]  S. Ramaswamy,et al.  Twist, a Master Regulator of Morphogenesis, Plays an Essential Role in Tumor Metastasis , 2004, Cell.

[165]  Cesario Z. Cerna,et al.  Activity of pivaloyloxymethyl butyrate, a novel anticancer agent, on primary human tumor colony-forming units , 2004, Investigational New Drugs.

[166]  M. Toyota,et al.  Identification of HRK as a target of epigenetic inactivation in colorectal and gastric cancer. , 2003, Clinical cancer research : an official journal of the American Association for Cancer Research.

[167]  Ni Ai,et al.  Tea polyphenol (-)-epigallocatechin-3-gallate inhibits DNA methyltransferase and reactivates methylation-silenced genes in cancer cell lines. , 2003, Cancer research.

[168]  H. McLeod,et al.  Disulfiram‐mediated inhibition of NF‐κB activity enhances cytotoxicity of 5‐fluorouracil in human colorectal cancer cell lines , 2003, International journal of cancer.

[169]  L. Berczi,et al.  Hypermethylation of the gene promoter and enhancer region can regulate Fas expression and sensitivity in colon carcinoma , 2003, Cell Death and Differentiation.

[170]  C. Britten,et al.  A phase I study of pivaloyloxymethyl butyrate, a prodrug of the differentiating agent butyric acid, in patients with advanced solid malignancies. , 2002, Clinical cancer research : an official journal of the American Association for Cancer Research.

[171]  W. Bodmer,et al.  Hypermethylation of the promoter region of the E-cadherin gene (CDH1) in sporadic and ulcerative colitis associated colorectal cancer , 2001, Gut.